The recommendations contained in this guideline are a consensus of the Alberta Cutaneous Tumour Team and are a synthesis of currently accepted approaches to management, derived from a review of relevant scientific literature. Clinicians applying these guidelines should, in consultation with the patient, use independent medical judgment in the context of individual clinical circumstances to direct care.
PubMed was again searched in 2013 for evidence on radiation therapy in cutaneous melanoma. The search term "melanoma" was used and results were limited to clinical trials, published between January 2012 and January 2013. Citations were hand-searched for studies pertaining to radiation therapy, resulting in one new phase III clinical trial. Updates to the National Comprehensive Cancer Network guideline (2013) on melanoma were cross referenced with this guideline as well. Following a review of the evidence by the Alberta Cutaneous Tumour Team, no changes to the recommendations were made.
Using the same search strategy, two relevant articles published between January 2013 and January 2014 were identified during the 2014 update. Following a review of the evidence by the Alberta Cutaneous Tumour Team, no changes were made to the recommendations.
TARGET POPULATION
The recommendations outlined in this guideline apply to adults over the age of 18 years with malignant melanoma. Different principles may apply to pediatric patients.
RECOMMENDATIONS
• Most patients with in-situ or early-stage melanoma (Stage 0; Stage 1A/B; Stage II, 1 mm thick with ulceration or Clark level IV, V or > 1 mm thick, any characteristic; and Stage III, sentinel node positive):  There is no recommendation for the use of adjuvant radiation therapy, as most of these patients will be cured by primary excision alone.  Post-operative radiotherapy may be used after close or positive margins where further excision is not practical or possible, inoperative lentigo maligna, rapid or multiple recurrences or extensive perineural spread (as seen with Desmoplastic melanoma). 5 • Patients with Stage IIIC or Stage IV disease should be referred for the consideration of adjuvant radiation therapy to improve local and regional control of their disease.  Radiation should not be given concurrently.  Interferon may act as a radiosensitizer, and patients receiving both may experience increased toxicities.  Radiation therapy may be delayed until completion of the induction phase of interferon administration.
DISCUSSION
Surgery is the primary treatment of patients with stage I-III melanoma. However, high recurrence rates have prompted attempts to develop effective adjuvant therapies after primary local and regional surgical interventions.
Primary indications for consideration of adjuvant radiation include nodal extracapsular extension (ECE), large lymph node size, multiple lymph nodes involved with metastatic disease, and recurrent disease after prior nodal surgery. Regional recurrence rates after surgical dissection alone when any one of these features is present range from 30-50%, although higher rates have been reported. [6] [7] [8] [9] [10] [11] [12] [13] [14] Additional high-risk features include macroscopic nodal disease, positive margins and head and neck lymph node location and consideration for patients with positive nodal disease who refuse dissection. [15] [16] [17] [18] A retrospective study by Ballo and colleagues involving 160 patients who had surgery followed by radiotherapy (30 Gy in 6 Gy fractions two times per week) revealed 10-year actuarial local, regional, and locoregional control rates of 94%, 94%, and 91%, respectively, and 10-year actuarial disease-specific, disease-free, and distant metastasis-free survival rates of 48%, 42%, and 43%, respectively. 19, 20 Similar control rates and survival rates have been reported from more recent retrospective studies. [21] [22] [23] [24] [25] [26] Strojan, et al. (2010) published retrospective data showing significant improvements in regional control at two years with the use of adjuvant radiotherapy (60 Gy in 2 Gy fractions five times per week) as compared to surgery alone (78 vs. 56%; P=.015) among patients with regionally advanced melanoma to the neck and/or parotid. 23 A prospective randomized controlled trial by Agrawal, et al. (2009) , among patients with clinically advanced, regional lymph node-metastatic disease (n=615), compared therapeutic lymphadenectomy and adjuvant radiotherapy with surgery alone and demonstrated a reduction in the regional recurrence rate (10.2 vs. 40.6%); furthermore, adjuvant radiotherapy was significantly associated with five-year regional control (P<.0001), distant metastasis-free survival (P=.0006), and disease-specific survival (P<.0001). 27 A more recent randomized trial compared adjuvant radiotherapy (48 Gy in 20 fractions) with observation, following lymphadenectomy among 217 patients with nodal metastases and a high risk of recurrence (based on number of nodes involved, extranodal spread, and maximum size of involved nodes). After a median follow-up of 40 months, the risk of lymph-node field relapse was found to be significantly reduced in the adjuvant radiotherapy group (20 relapses in RT vs. 34 in observation; HR 0.56, 95% CI 0.32-0.98; p=.041). However, there were no differences in relapse-free survival (70 events vs. 73, HR 0.91, 95% CI 0.65-1.26; p=.56) or overall survival (59 deaths vs. 47, HR 1.37, 95% CI 0.94-2.01; p=.12). 28 The axillary control rate with adjuvant radiotherapy versus surgery alone has been reported to be as high as 87%. However, the risk of adjacent-field recurrences with the use of radiotherapy (OR 4.27, 95% CI 1.25-14.57; p=0.02) should be considered when planning radiotherapy. 29 Current guidance from the National Comprehensive Cancer Network supports the use of adjuvant radiotherapy, based on lower level evidence. The guideline states that adjuvant radiation may be considered in special cases where adequate surgical treatment is not possible, for selected patients with desmoplastic melanoma with extensive neurotrophism, and for patients at significant risk of nodal basin relapse. The suggested regimen is 30-60 Gy (2-6 Gy per fraction) over 2.5-6 weeks. 30
DISSEMINATION
• Present the guideline at the local and provincial tumour team meetings and weekly rounds.
• Post the guideline on the Alberta Health Services website.
• Send an electronic notification of the new guideline to all members of CancerControl Alberta.
MAINTENANCE
A formal review of the guideline will be conducted at the Annual Provincial Meeting in 2016. If critical new evidence is brought forward before that time, however, the guideline working group members will revise and update the document accordingly.
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